Associated Papers
PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.
Nixon MJ et al.
Npj Breast Cancer, 2019
31552290 (PubMed )
Supplement: 41523_2019_126_MOESM1_ESM.xlsx › Supplementary_Dataset_1
Select a paper to view details